ECARX Holdings Inc. (ECX) Financial Statements
ECARX Holdings Inc. (ECX) reported trailing twelve-month revenue of $881.3M (up 9.9% year on year) and net income of -$18.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$158.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ECXECARX Holdings Inc.Follow ECX — free
—
Price chart with a free account
- Market cap
- 334.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Revenue | 515.7 | 662.2 | 771.5 | 847.9 | 881.3 | |
| Gross profit | 143.6 | 178.6 | 160.1 | 161.3 | 184.0 | |
| Research & development | 175.6 | 177.7 | 174.9 | 123.3 | — | |
| Operating income | -212.6 | -130.0 | -122.9 | -54.8 | -8.8 | |
| Pre-tax income | -220.3 | -144.4 | -137.5 | -67.7 | -19.1 | |
| Income tax | 3.1 | -0.5 | 0.2 | 1.2 | 0.2 | |
| Net income | -223.2 | -133.3 | -129.8 | -66.0 | -18.0 | |
| Diluted EPS ($) | -1.15 | -0.40 | -0.39 | -0.20 | -0.06 | |
| Diluted shares (mn) | 239.3 | 337.4 | 336.6 | 338.7 | — |
USD millions · SEC XBRL
ECARX Holdings Inc. — questions
- What is ECARX Holdings Inc.'s revenue?
- $881.3M over the twelve months to 2026-06-30, up 9.9% year on year, from its 10-Q and 10-K filings.
- What is ECARX Holdings Inc.'s net income?
- -$18.0M over the twelve months to 2026-06-30.
- What is ECARX Holdings Inc.'s free cash flow?
- -$158.6M over the twelve months to 2026-06-30.
- What are ECARX Holdings Inc.'s diluted earnings per share?
- $-0.06 over the twelve months to 2026-06-30.
Every figure on this page comes from ECARX Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.